Sharp Therapeutics Corp.
SHRX.V
TSX
| 09/30/2025 | 06/30/2025 | 09/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | -294.15% | 117.18% | 62.35% | ||
| Total Depreciation and Amortization | 9.57% | -14.50% | -46.99% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 103.81% | -198.18% | -97.69% | ||
| Change in Net Operating Assets | -639.02% | 116.12% | -145.60% | ||
| Cash from Operations | 16.85% | 3.38% | -28.28% | ||
| Capital Expenditure | -- | -- | -100.00% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -100.00% | ||
| Total Debt Issued | -- | -- | -24.00% | ||
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | ||
| Issuance of Common Stock | -99.73% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -101.78% | 4,964.20% | -100.00% | ||
| Foreign Exchange rate Adjustments | -88.89% | 276.54% | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | 280.00% | ||
| Net Change in Cash | -202.11% | 177.16% | -22.31% | ||